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ABSTRACT 
Objective: A new simple, accurate, precise, robust, reproducible and economic RP-HPLC method was developed for Phenylephrine Hydrochloride 
and Ebastine in marketed tablet dosage form.  
Methods: The Chromatographic separation was achieved on Thermo BDS Hypersil C18 column (250 mm × 4.6 mm, 5 µm) at ambient temperature. 
Mobile phase consist of Methanol: Phosphate buffer (30:70v/v), pH 4.0±0.05 was pumped at a flow rate was 1.0 ml/ min and Quantification was 
achieved with photodiode array (PDA) detection at 215 nm.  
Results: The method was linear over the concentration range of 5-15 µg/mL (r2 = 0.9994) for Phenylephrine Hydrochloride (PHE) and 5-15 µg/mL 
(r2 = 0.9947) for Ebastine (EBS). The percentage content for PHE and EBS was found to be 101.08±0.74% and 99.11±0.52%, respectively in the 
marketed formulation. The LOD and LOQ values for PHE were 0.46 and 1.12 µg/ml, respectively and these values for EBS were 1.41 and 3.41 µg/ml, 
respectively. These values indicate the sensitivity of method. Percent recovery was 99.69% for PHE and 96.60% for EBS reflects the good accuracy 
of the method. The developed method was validated for linearity, precision, accuracy, and robustness as per ICH guideline. 
Conclusion: A simple, precise, accurate, linear and rapid RP-HPLC method was developed and validated as per ICH guidelines. The results suggest 
that the developed can be applicable in routine analysis for tablets in the pharmaceutical industry. 
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INTRODUCTION 
The combination of Phenylephrine Hydrochloride and Ebastine has 
synergistic effect for the treatment of common cold and allergy [1]. 
Phenylephrine Hydrochloride is a selective α1 agonist, it causes 
vasoconstriction by stimulating the post-synaptic α receptors. It is 
constituent of most of orally administered nasal decongestant 
preparations [2]. Phenylephrine Hydrochloride is chemically (R)-1-
(3-hydroxyphenyl)-2- methylamino-ethanol hydrochloride [3] 
(Figure 1). It is official drug in Indian Pharmacopoeia [5], British 
Pharmacopoeia [6]. Ebastine is second generation H1 receptor 
agonist and non sedating antihistamine drug. It is used for 
symptomatic relief of allergic conditions, including rhinitis and 
pruritic skin disorder [4,7]. Ebastine chemically known as 4-(4-
benzhydryloxy-1-piperidyl)-1-(4- tert-butyl phenyl) butan-1- one 
[3] (Figure 2). Ebastine is official in British Pharmacopoeia [6] and 
European Pharmacopoeia [8].  
Literature review revealed that several UV-Spectrophotometric 
methods [9], Electrochemical Determination [10], UPLC [11] and RP- 
HPLC [12, 13] methods have been developed for estimation of 
Ebastine. Similarly, UV-Spectrophotometric method [14], RP-HPLC 
[15], LC-MS-MS in plasma [16] methods have been developed for 
Phenylephrine Hydrochloride as single drug or combination of other 
drugs. The combination of Phenylephrine Hydrochloride and 
Ebastine is more effective for the treatment of allergy and 
decongestant without causing sedation as other antihistamine drugs. 
The objective of this work was to develop and validate a simple, 
accurate, precise, robust, reproducible and economic method for 
determination of Phenylephrine Hydrochloride and Ebastine in bulk and 
combined pharmaceutical dosage form as per ICH guidelines [17]. 
 
 
Fig. 1: Chemical structure of Phenylephrine Hydrochloride 
 
Fig. 2: Chemical structure of Ebastine 
 
MATERIALS AND METHODS 
Reagents and Materials 
Phenylephrine Hydrochloride and Ebastine reference standard (RS) 
was obtained from Molecule Laboratory Pvt Ltd, Ahmedabad, India. 
The commercial fixed dose combination product containing 10 mg 
Ebastine and 10 mg Phenylephrine Hydrochloride (EBAST-
DC®Micro Lab, India) was procured from the local pharmacy. 
Methanol (HPLC grade) and potassium dihydrogen phosphate of AR 
grade was obtained from Merck Ltd., Mumbai, India and S.D Fine 
Chemicals Ltd, Mumbai, India, respectively.  
Instrument and Apparatus  
Chromatographic separation was performed using a HPLC 
instrument (LC-2010CHT, Shimadzu, Japan) equipped with a 
photodiode array detector, manual injector with 20 µL loop system. 
Spinchrome software was employed for data collection and 
processing [21, 22]. Chromatographic separation was performed on 
BDS Hypersil C18 stainless steel column (250×4.6 mm, 5 µm). Digital 
pH meter (Metler Toledo) and Analytical balance (Metler Toledo) 
were employed for this study. 
Chromatographic Condition 
Stationary phase BDS Hypersil C18 was used. Mobile Phase comprised 
of Methanol: Phosphate buffer (30:70v/v), pH 4.0±0.05, Flow rate 1.0 
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mL/min, Injection volume 20 µL, HPLC analysis [18-20] was 
performed at ambient temperature with detection at 215 nm. 
Preparation of mobile phase 
Mobile phase used in a combination of 70:30 v/v of Phosphate buffer 
(0.05M): Methanol. Mobile phase was sonicate and filtered through 
0.22µ nylon filter for 15 minutes in an ultrasonicator. 
Preparation of mixed standard stock solutions  
Mixed standard solution was prepared by transferring accurately 
weighed Phenylephrine Hydrochloride (10mg) and Ebastine (10mg) 
into a 100 ml volumetric flask. 50 ml of methanol was added to it 
and the solution was sonicated for 2 min. Then volume was made to 
100 ml to obtain the final concentration 100 µg/ml. 
Analysis of Marketed Formulation 
20 tablets were accurately weighed and average weight was 
calculated. Then tablets were ground into a fine powder using a 
glass mortar and pestle. Powder equivalent to 10 mg of 
Phenylephrine Hydrochloride and Ebastine as well as accurately 
weighed and transferred to a 100 ml volumetric flask. 
Approximately 50 ml of mobile phase was added to the flask and the 
contents were sonicated for 15 min. Volume was adjusted upto the 
mark. The resulting solution was filtered using 0.22µ nylon filter. 
This sample stock solution was further diluted with the same mobile 
phase to obtain 10 µg/ml of Phenylephrine Hydrochloride and 10 
µg/ml of Ebastine. The sample solutions were prepared in triplicate 
and 20 µl volume of each sample solution was injected into the 
sample injector of RP-HPLC under the optimized chromatographic 
conditions. The concentrations of the drugs in samples were 
calculated by measuring their peak areas and comparing with peak 
areas of standard drug solutions of respective concentrations. 
Method validation 
Validation of an analytical procedure is the process by which 
laboratory studies that the performance characteristics of the 
procedure meet the requirements for the intended analytical 
application. The developed chromatographic method was validated 
for system suitability, linearity & range, accuracy, precision, and 
robustness, as per ICH guidelines [18]. 
System suitability test 
The system suitability test was performed by injecting five replicate 
of working standard solution. Results of retention time, theoretical 
plates and tailing factor (peak symmetry) were presented in Table 2. 
Linearity and range 
Working solutions of Phenylephrine Hydrochloride (5-15μg/ml) and 
Ebastine(5-15μg/ml) were injected under the operating 
chromatographic conditions and peak areas for each drug were 
calculated at 215 nm. The calibration curve was plotted between 
areas against corresponding concentrations of each drug. Linear 
regression data for calibration curves were shown in Table 3. The 
range of solution has been decided according to correlation 
coefficient of regression equation. 
Accuracy (% recovery) 
The accuracy of the method was determined by calculating % 
recovery of each drug by standard addition method. Percent 
recovery of Phenylephrine Hydrochloride and Ebastine was 
determined at three different level 80%, 100% and 120% of the 
target concentration in triplicate (Table 4). 
Precision 
Method Precision (Repeatability) was determined by injecting 
standard solution six times. The retention times and peak areas of 
six replicates are recorded. The intermediate (intra-day and inter-
day) precision study of Phenylephrine Hydrochloride and Ebastine 
was carried out by estimating the corresponding responses three 
times on the same day and on three different days for the 
concentrations level at 50%, 100%, 150% of Phenylephrine 
Hydrochloride and 50%, 100%, 150% of Ebastine.  
The precision is expressed as the % RSD of Peak areas and it should 
not be more than 2%. Precision study for Phenylephrine 
Hydrochloride and Ebastine were mentioned in Table 5 and 6. 
Robustness 
Robustness of the method was studied by changing flow rate (±0.2 
ml/min), change in pH (±0.2), and change in mobile phase 
concentration (±2% v/v) during analysis. Sample solution of 100% 
concentration is prepared and injected in triplicate for every 
condition and %RSD was calculated for each condition (Table 7). 
LOD and LOQ 
The standard deviation of the Y-intercept and average slope of the 
calibration curve was used to calculate LOD and LOQ using following 
formulae [23] (Table 8).  
LOD =  
.		





LOD - Limit of detection, 
LOQ – Limit of quantitation  
Where, S is average value of slopes of calibration plots and SD is 
calculated using values of y intercepts of regression equations. 
RESULTS AND DISCUSSION 
The composition, flow rate of mobile phase and column as well as 
column temperature was suitably optimized for better separation of 
Phenylephrine Hydrochloride and Ebastine combined dosage form. 
Finally, potassium dihydrogen phosphate (0.05M KH2PO4) Buffer: 
Methanol (70:30v/v) at pH 4.0±0.5, 1 ml/min. flow rate and Hypersil 
BDS C18 column at ambient temperature was selected.  
These optimized conditions had following system suitability 
parameters. Number of theoretical plates for Phenylephrine 
Hydrochloride and Ebastine were 6724 and 7099, respectively.  
Tailing Factors for Phenylephrine Hydrochloride and Ebastine were 
1.39 and 1.40, respectively. LOD and LOQ for Phenylephrine 
Hydrochloride was 0.46 and 1.12 that for Ebastine was 1.41 and 3.41 
respectively (Table 8). Low value of LOD and LOQ shows that 
method is sensitive and can be apply for detection of lowest amount 
of analyt. The retention time for Phenylephrine Hydrochloride and 
Ebastine were 3.60 and 5.84 min., respectively.  
The values of correlation coefficient for Phenylephrine 
Hydrochloride and Ebastine (Table 2) demonstrated the good 
relationship between peak area and concentration. Therefore, the 
developed method was linear in concentration range of 5-15 µg/mL 
for Phenylephrine Hydrochloride and 5-15µg/mL for Ebastine. The 
percentage assay of Phenylephrine Hydrochloride and Ebastine in 
tablets was 101.08% and 99.11%, respectively (Table 1).  
 
 
Fig. 3: Standard Solution of Phenylephrine HCl and Ebastine 
Peak 1.Phenylephrine HCl 2.Ebastine 
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Fig. 4: Sample solution of Phenylephrine HCl and Ebastine 
Peak 1.Phenylephrine HCl 2.Ebastine 
 
Percent recovery was 99.69% for Phenylephrine Hydrochloride and 
96.60% for Ebastine demonstrated accuracy. The low value of % 
RSD in intra-day and inter-day precision (Table 5 and 6) indicated 
reproducibility of this method. Finally, deliberate variations were 
made to check the significant variations in experimental conditions 
(Table 7) suggested robustness of developed method. 
 
 
Fig. 5: Calibration curve of Phenylephrine HCl 
 
Table 1: Results of Assay of Marketed formulation 







Ebastine 10 99.11± 0.5186 0.986 
Phenylephrine 
HCl 
10 101.08± 0.738 0.730 
*n=3 
 
Fig. 6: Calibration curve of Ebastine 
 
Table 2: Results of system suitability test 
Parameters Ebastine Phenylephrine HCl 
Retention time (min) 3.605 5.847 
Tailing factor 1.391 1.405 
Theoretical plates 6724 7099 
Resolution  9.915 
 
Table 3: Linear regression data for calibration curves of 
Phenylephrine HCl and Ebastine 
Parameters Ebastine Phenylephrine HCl 
Linearity range (µg/ml) 5-15 5-15 
Coefficient of correlation 0.9994 0.9947 
Slope± SD* 643.848 ± 182 446.75± 126 
Intercept 27.25 0.391 
*n=5 
Table 4: Accuracy data of Phenylephrine HCl and Ebastine 
Drug Level Amount of  
sample taken  
(µg/mL) 
Amount of  
standard spiked  
(µg/mL) 
Mean 
% Recovery ± SD* 
%RSD* 
Phenylephrine HCl 80% 5 4  99.82±1.12  1.254  
100% 5 5  99.66±0.75 0.749 
120% 5 6  99.59±0.32 0.324 
Ebastine 80% 5 4  99.94±1.12 1.124 
100% 5 5  99.25±0.23  0.234 
120% 5 6  99.60±0.59  0.594 
*n=3  
Table 5: Results for method precision (Repeatability) 
Drug Concentration of drug (µg/ml) Area (Mean ± SD *) % RSD* 
Phenylephrine HCl 10 1277.75±4.8363 0.3785 
Ebastine 10 1802.384±10.153 0.5633 
*n=6 
Table 6(a): Results for intermediate precision (Inter-day) 
Interday 
Conc. Phenylephrine HCl Ebastine 
 %RSD* %RSD* 
50 %  0.7113 0.6626 
100 %  0.7762 0.7448 
150 %  0.4650 0.8864 
*n=3 
Jain et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 8, 466-470 
469 
Table 6(b): Results for intermediate precision (intra-day) 
Intraday 
Conc.  Phenylephrine HCl Ebastine 
 %RSD* %RSD* 
50 %  0.9282 0.5530 
100 %  0.9077 1.0642 
150 % 0.6068 0.7164 
*n=3 
 
Table 7: Robustness studies of Phenylephrine HCl and Ebastine 
Change in flow rate 
(1 ml/min ± 0.2 ml/min) 
   
 Flow rate (ml/min) Area 
(Mean±SD*) 
%RSD* 
Phenylephrine HCl 1.2 ml/min 1250.113±17.62 1.41 
0.8 ml/min 1326.512±19.11 1.44 
Ebastine 1.2 ml/min 1754.164±32.76 1.86 
0.8 ml/min 1872.860±17.77 0.94 
Change in mobile phase composition 
(± 2% v/v) 
   





Phenylephrine HCl (72:28) v/v 1250.164±32.76 1.11 
(68:32) v/v 1313.800±14.04 1.06 
Ebastine (72:28) v/v 1762.058±17.22 0.97 
(68:32) v/v 1853.114±15.28 0.82 
Change in pH 
(4.0±0.2) 
   





Phenylephrine HCl 4.2 1226.226±14.47  1.18 
3.8 1315.910±14.13 1.07 
Ebastine 4.2 1723390±17.64 1.02 
3.8 1852.540±15.69 0.84 
 *n=3 
Table 8: LOD and LOQ 
Parameters Phenylephrine HCl Ebastine 
LOD (µg/ml) 1.12 0.46 
LOQ (µg/ml) 3.41 1.41 
 
CONCLUSION 
It can be concluded from the results that the proposed RP-HPLC 
method was found to be simple, accurate, robust, precise, 
reproducible and economic for the analysis Phenylephrine 
Hydrochloride and Ebastine in bulk and tablet dosage forms. This 
method was validated as per ICH guidelines. Thus, it can be used for 
routine quality control studies for assay of Phenylephrine 
Hydrochloride and Ebastine. 
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